Treatment strategy
|
Total cost (USD)
|
Incremental cost (USD)
|
Total LY
|
LY saveda
|
ICER per LY saved
|
---|
Vancomycin
|
16,346
| |
9.84
| | |
Teicoplanin
|
12,487
|
− 3858
|
10.80
|
0.96
|
Dominant
|
Linezolid
|
19,230
|
2884
|
11.16
|
1.32
|
2185
|
- USD US dollar, LY life-years, ICER incremental cost-effectiveness ratio
- aCalculated as the average cost per patient and the average number of LY per patient in this strategy minus those of the treatment of vancomycin